Publication:
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Thumbnail Image
Identifiers
URI: http://hdl.handle.net/20.500.12105/18521
DOI: 10.1111/ctr.14550
Full text access: http://hdl.handle.net/10668/19932

Publication date

2021-12-17

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publishers

Metrics
Google Scholar
Export
MarcXML METS

Research Projects

Organizational Units

Journal Issue

Abstract

Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P 

Description

Keywords

bioavailability clinical practice pharmacokinetics renal transplantation tacrolimus treatment failure

MeSH Terms

Biological Availability Drug Administration Schedule Graft Rejection Humans Immunosuppressive Agents Kidney Transplantation Prospective Studies Tacrolimus Transplant Recipients

DeCS Terms

Bibliographic citation

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)

Publisher version

Related dataset

Related publication

Document type

research article